INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 128 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2016. The put-call ratio across all filers is 3.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $961,061 | -17.5% | 18,450 | +0.3% | 0.00% | 0.0% |
| Q2 2023 | $1,164,645 | +24.0% | 18,393 | +6.0% | 0.00% | 0.0% |
| Q1 2023 | $939,448 | -9.5% | 17,349 | -11.6% | 0.00% | -25.0% |
| Q4 2022 | $1,038,396 | +23.6% | 19,622 | +8.9% | 0.00% | +33.3% |
| Q3 2022 | $840,000 | -16.6% | 18,025 | +2.2% | 0.00% | 0.0% |
| Q2 2022 | $1,007,000 | -33.2% | 17,638 | -28.4% | 0.00% | 0.0% |
| Q1 2022 | $1,507,000 | +7.0% | 24,633 | -8.5% | 0.00% | 0.0% |
| Q4 2021 | $1,408,000 | +42.8% | 26,913 | +1.8% | 0.00% | 0.0% |
| Q3 2021 | $986,000 | -26.6% | 26,437 | -19.7% | 0.00% | -25.0% |
| Q2 2021 | $1,344,000 | +37.0% | 32,924 | +13.8% | 0.00% | +33.3% |
| Q1 2021 | $981,000 | +13.9% | 28,924 | +6.9% | 0.00% | 0.0% |
| Q4 2020 | $861,000 | +77.9% | 27,061 | +43.5% | 0.00% | +50.0% |
| Q3 2020 | $484,000 | +4.3% | 18,858 | +4.2% | 0.00% | 0.0% |
| Q2 2020 | $464,000 | +149.5% | 18,094 | +49.7% | 0.00% | +100.0% |
| Q1 2020 | $186,000 | -69.9% | 12,088 | -32.8% | 0.00% | -66.7% |
| Q4 2019 | $617,000 | +314.1% | 17,988 | -10.1% | 0.00% | +200.0% |
| Q3 2019 | $149,000 | -44.8% | 20,010 | -4.0% | 0.00% | -50.0% |
| Q2 2019 | $270,000 | -5.9% | 20,835 | -11.7% | 0.00% | 0.0% |
| Q1 2019 | $287,000 | +8.3% | 23,594 | +1.4% | 0.00% | 0.0% |
| Q4 2018 | $265,000 | -56.1% | 23,276 | -16.2% | 0.00% | -50.0% |
| Q3 2018 | $603,000 | +18.2% | 27,791 | -3.8% | 0.00% | +33.3% |
| Q2 2018 | $510,000 | -20.9% | 28,884 | -5.8% | 0.00% | -25.0% |
| Q1 2018 | $645,000 | +24.8% | 30,661 | -14.1% | 0.00% | 0.0% |
| Q4 2017 | $517,000 | +22.2% | 35,705 | +33.3% | 0.00% | 0.0% |
| Q3 2017 | $423,000 | +34.7% | 26,776 | +6.0% | 0.00% | +33.3% |
| Q2 2017 | $314,000 | -28.5% | 25,269 | -6.6% | 0.00% | -40.0% |
| Q1 2017 | $439,000 | -14.8% | 27,045 | -20.7% | 0.01% | -16.7% |
| Q4 2016 | $515,000 | +146.4% | 34,098 | +778.6% | 0.01% | +100.0% |
| Q4 2015 | $209,000 | – | 3,881 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |